Paper41368474
Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?
Elmustafa F and 6 others. Curr Hepatol Rep, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes? Papers, record 41368474. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41368474
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| U01 AA026980 | NIAAA NIH HHS | United States | U01AA026980 | PubMed and NIH |
Source NIH RePORTER
References128
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36644237 | A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. | JHEP Rep | 2023 | https://conductscience.org/library/papers/36644237 | PubMed |
| 2 | 26707137 | Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. | Dig Dis Sci | 2016 | https://conductscience.org/library/papers/26707137 | PubMed |
| 3 | 38534155 | Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes. | Am J Gastroenterol | 2024 | https://conductscience.org/library/papers/38534155 | PubMed |
| 4 | 23355498 | Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. | Am J Epidemiol | 2013 | https://conductscience.org/library/papers/23355498 | PubMed |
| 5 | 38664876 | Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. | Aliment Pharmacol Ther | 2024 | https://conductscience.org/library/papers/38664876 | PubMed |
| 6 | 36626630 | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. | Hepatology | 2023 | https://conductscience.org/library/papers/36626630 | PubMed |
| 7 | 22435761 | Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. | Liver Int | 2012 | https://conductscience.org/library/papers/22435761 | PubMed |
| 8 | 38806481 | Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. | Nat Commun | 2024 | https://conductscience.org/library/papers/38806481 | PubMed |
| 9 | 38428619 | Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among US Veterans With Steatotic Liver Disease. | Gastroenterology | 2024 | https://conductscience.org/library/papers/38428619 | PubMed |
| 10 | 35750137 | Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. | J Hepatol | 2022 | https://conductscience.org/library/papers/35750137 | PubMed |
| 11 | 35468325 | Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. | Lancet Diabetes Endocrinol | 2022 | https://conductscience.org/library/papers/35468325 | PubMed |
| 12 | 14984242 | Ethyl glucuronide--the direct ethanol metabolite on the threshold from science to routine use. | Addiction | 2003 | https://conductscience.org/library/papers/14984242 | PubMed |
| 13 | 38820071 | MetALD: Does it require a different therapeutic option? | Hepatology | 2024 | https://conductscience.org/library/papers/38820071 | PubMed |
| 14 | 35798021 | The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35798021 | PubMed |
| 15 | 33440159 | Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. | Cell Rep | 2021 | https://conductscience.org/library/papers/33440159 | PubMed |
| 16 | 38266957 | Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up. | Metabolism | 2024 | https://conductscience.org/library/papers/38266957 | PubMed |
| 17 | 35761115 | Alcoholic liver disease: a new insight into the pathogenesis of liver disease. | Arch Pharm Res | 2022 | https://conductscience.org/library/papers/35761115 | PubMed |
| 18 | 40517819 | Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. | J Hepatol | 2025 | https://conductscience.org/library/papers/40517819 | PubMed |
| 19 | 38174913 | ACG Clinical Guideline: Alcohol-Associated Liver Disease. | Am J Gastroenterol | 2024 | https://conductscience.org/library/papers/38174913 | PubMed |
| 20 | 40283027 | Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40283027 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42872032 | Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice? | Hepatobiliary Surg Nutr | 2026 | https://conductscience.org/library/papers/42872032 | PubMed |
| 42577825 | Pharmacologic management of metabolic and alcohol-associated liver disease. | Metab Target Organ Damage | 2026 | https://conductscience.org/library/papers/42577825 | PubMed |
| 42227036 | Precision pathophysiology in steatotic liver disease. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/42227036 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41368474
GET https://conductscience.org/api/papers/v1/41368474/references?page=2